
Biopharmaceutical firm, Reset Therapeutics, innovates modulation therapies for the human circadian system.
Reset Therapeutics, founded with a mission to revolutionize biopharmaceutical treatments, focuses on developing and commercializing therapies that modulate the human circadian system. Their innovative products aim to address various health conditions by targeting the body's internal clock, offering potential solutions for disorders related to sleep, metabolism, and other circadian rhythm-related issues.
Notable figures in the company include leading scientists and industry experts dedicated to advancing circadian modulation therapies. Reset Therapeutics has garnered attention from prominent investors in the biotech sector, reflecting confidence in their groundbreaking approach. Their achievements in preclinical and clinical trials underscore their impact on the biopharmaceutical landscape, positioning them as pioneers in circadian system modulation.

Reset Pharmaceuticals

Synchronicity Pharma

Faze Medicines
fazemed.com

Retro Biosciences
retro.bio

Fuse Biotherapeutics
fusebiotx.com

Thesan Pharmaceuticals
thesanpharma.com

Rectify Pharmaceuticals
rectifypharma.com

Reservoir Neuroscience
reservoirneuro.com

Eikon Therapeutics
eikontx.com

Epic-Bio
epic-bio.com

NeuroTherapeutics Pharma

Remix Therapeutics

Celsius Therapeutics
celsiustx.com

Akttyva Therapeutics
akttyva.com

Nested Therapeutics
nestedtx.com
Companies similar to Reset Therapeutics include Reset Pharmaceuticals, Synchronicity Pharma, Faze Medicines and Retro Biosciences.
Reset Therapeutics was founded in 2008.
Reset Therapeutics' headquarters is located in South San Francisco, CA, US.
Reset Therapeutics' most recent funding round was for $29.7M (USD) in February 2016.
As of Feb 19, 2016, Reset Therapeutics has raised a total of $53.6M (USD).
Reset Therapeutics has 30 employees as of Feb 4, 2024.